Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-23
2005-08-23
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S250000, C514S251000
Reexamination Certificate
active
06933285
ABSTRACT:
Compounds comprising flavin N-oxides for treatments of solid tumors, non-solid tumor masses, leukemias, and non-small cell lung cancers and for eradicating contaminants in blood products. Methods of treating patients having solid type cancers comprising administering a therapeutically effective amount of a flavin N-oxide to a subject in need of treatment and exposing the flavin N-oxide to an activator such that activation of the flavin N-oxide results in damage to the DNA in the cancer cells without substantial damage to the DNA of normal cells are also provided. Methods of using a flavin N-oxide as part of a combination therapy with chemotherapy, radiation therapy, or both are also provided. Methods of reducing pathogenic bacterial or viral contamination in a composition comprising a) mixing the composition with an efficacious amount of a flavin N-oxide and b) exposing the mixture of the composition and the flavin N-oxide to an activator for a period of time sufficient to activate the flavin N-oxide such that the flavin N-oxide reduces the contamination in the composition are also provided. Preferably, the composition is a blood product selected from plasma, platelets, and red blood cells and the activator is an enzyme.
REFERENCES:
patent: 5945420 (1999-08-01), Araki et al.
patent: 6177441 (2001-01-01), Cook et al.
patent: 6258577 (2001-07-01), Goodrich, et al.
patent: 6503699 (2003-01-01), Wollowitz et al.
patent: 6514987 (2003-02-01), Cook et al.
patent: 2002/0028432 (2002-03-01), Cook et al.
patent: 2002/0182581 (2002-12-01), Cook et al.
Gura (Science, 1997, 278(5340):1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Hartwell et al (Science, 1997, 278(5340):1064-1068).
Fersi, Hannan, M.S., “Binding Affinities of Sensitizers of Pathogen Eradication and Photochemical Behavior of Riboflavin and Riboflavin-N-Oxide,” A Thesis, 2002, The Ohio State University.
Brown, J.M., “SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours,”Br. J. Cancer67, pp. 1163-1170, 1993, Macmillan Press Ltd.
Daniels, J. Scott et al., “DNA Cleavage by the Antitumor Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (SR4233): Evidence for Involvement of Hydroxyl Radical,”J. Am. Chem. Soc.,118, pp. 3380-3385, 1996, American Chemical Society.
Brown, J.M., “Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies,”Molecular Medicine Today,vol. 6, pp. 157-162, London, UK, 2000.
Kelson, Andrew B. et al., “1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity,”Anti-Cancer Drug Design,13, pp. 575-592, Oxford Univ. Press, 1998.
Brown, J.M., “The Hypoxic Cell: A Target for Selective Cancer Therapy—Eighteenth Bruce F. Cain Memorial Award Lecture,”Cancer Research,59, pp. 5863-5870, Stanford, CA, Dec. 1, 1999.
Brown, J.M. et al., “Tirapazamine: laboratory data relevant to clinical activity,”Anti-Cancer Drug Design,13, pp. 529-539, Oxford Univ. Press, 1998.
Evans, James W. et al., “Tirapazamine is Metabolized to Its DNA-damaging Radical byIntranuclear Enzymes,”Cancer Research,58, pp. 2098-2101, Stanford, CA, May 15, 1998.
Daniels, J.S. et al., “Photochemical DNA Cleavage by the Antitumor Agent 3-Amino-1,2,4-Benzotriazine 1,4-Dioxide (Tirapazamine, WIN 59075, SR4233),”The Journal of Organic Chemistry,vol. 63, No. 26, pp. 10027-10030, American Chemical Society, 1998.
Patterson, Laurence H. et al., “Electron Paramagnetic Resonance Spectrometry Evidence for Bioreduction of Tirapazamine to Oxidising Free Radicals Under Anaerobic Conditions,”Biochemical Pharmacology,Vo. 60, pp. 1933-1935, Elsevier Science Inc., 2000.
Fieschi, Franck et al., “The Mechanism and Substrate Specificity of the NADPH: Flavin Oxidorductase fromEscherichia Coli”.,Journal of Biological Chemistry, Dec. 1995, vol. 270, No. 51, pp. 30392-30400.
Xun, Luying et al., “Characterization of 4-Hydroxyphenylacetate 3-Hydroxylase (HpaB) ofEscherichia colias a Reduced Flavin Adenine Dinucleotide-Utilizing Monooxygenase,”Applied and Environmental Microbiology, Feb. 2000, vol. 66, No. 2, pp. 481-486.
Niviere, Vincent et al.., “Is the NAD(P)H: Flavin Oxidoreductase fromEscherichia colia Member of the Ferredoxin-NADP+ Reductase Family?”The Journal of Biological Chemistry, Jul. 12, 1996, vol. 271, No. 28, pp. 16656-16662, The American Society for Biochemistry and Molecular Biology, Inc.
Niviere, Vincent et al.., “The NAD(P)H: Flavin Oxidoreductase fromEscherichia coli,”The Journal of Biological Chemistry, Jun. 25, 1999, vol. 274, No. 26, pp. 18252-18260, The American Society for Biochemistry and Molecular Biology, Inc.
Woodmansee, Anh N. et al., “Reduced Flavins Promote Oxidative DNA Damage in Non-respiringEscherichia coliby Delivering Electrons to Intracellular Free Iron,”The Journal of Biological Chemistry, Sep. 13, 2002, vol. 277, No. 37, pp. 34055-34066, The American Society for Biochemistry and Molecular Biology, Inc.
Kasim, Mumtaz, “The Role of the N(5) Interaction and Associated Conformational Changes in the Modulation of the Redox Properties in Flavoproteins,” Dissertation, 2002, 208 pages.
Calfee Halter & Griswold LLP
Henry Michael C.
The Ohio State University
Wilson James O.
LandOfFree
Flavin N-oxides: new anti-cancer agents and pathogen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Flavin N-oxides: new anti-cancer agents and pathogen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Flavin N-oxides: new anti-cancer agents and pathogen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3494890